Publication | Open Access

Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues

OncologyPancreatic CancerMedicineDiabetesLonger Progression-free SurvivalPathologyMetformin UseSomatostatin AnaloguesPharmacologyRadiation OncologyEndocrine-related Cancer